3Daughters, a clinical development company dedicated to advancing women’s healthcare, has announced the successful completion of an oversubscribed seed financing round, raising $4.7 million. This round saw participation from existing investors including Thairm Bio, Argosy Foundation, Wexford Science and Technology, UMass Amherst, and new undisclosed investors. Mary Beth Cicero, CEO of 3Daughters, commented: “We are thrilled by the overwhelming response from both…
French healthtech company Sonio, has introduced Soniopedia, a new cloud-based AI-powered software designed for prenatal ultrasound training. This announcement was made at the World Congress of Fetal Medicine (FMF) in Lisbon. Soniopedia aims to address the training challenges in prenatal ultrasound by simulating cases from the initial ultrasound image to the necessary genetic tests within a single cloud-based platform. Prenatal medicine is…
The European Society of Human Reproduction and Embryology (ESHRE) has launched the Female Reproductive Genetics Initiative (FeRGI), a project aimed at translating genetic research in infertility into clinical practice. Developed within the Special Interest Group (SIG) Reproductive Genetics, FeRGI focuses on providing resources and training to clinicians and biologists to improve the diagnosis and treatment of female infertility. Recent advancements over the…
At the ESHRE Annual Meeting in Amsterdam, data presented revealed that women in Europe are undergoing more cycles of in vitro fertilisation (IVF) and intrauterine insemination (IUI). The data from the ESHRE European IVF Monitoring (EIM) Consortium indicates a steady rise in the use of Assisted Reproductive Technology (ART). In 2021, a total of 1,103,633 ART treatment cycles were reported by 1,382…
It’s 2024. We still don’t know what causes PCOS. We don’t know how to cure it. And we have a limited understanding how to treat it properly. PCOS stands for Polycystic Ovary Syndrome. It’s a syndrome because we don’t really understand it. It’s a syndrome because in medicine ‘syndrome’ refers to a group or collection of symptoms and signs that consistently occur…
Oxolife, a biotech company specializing in female fertility, has announced promising results from a Phase 2 clinical trial of its non-hormonal fertility pill, OXO-001, at the European Society of Human Reproduction and Embryology (ESHRE) 40th Annual Meeting in Amsterdam. The data indicates that OXO-001 significantly improves embryo implantation, pregnancy, and live birth rates in women undergoing in-vitro fertilization (IVF) and intracytoplasmic sperm…
Mira, a hormonal health company providing at-home reproductive health solutions, launches an online Hormone Health Clinic for Fertility aimed to help people – struggling to conceive. The clinic provides personalized support from fertility professionals throughout the conception journey, focusing on addressing hormonal imbalances, streamline nutrition and gut health, setting up effective exercise routines and improving mental health. 1 in 5 people in the US are affected by…
Gynaecological health startup Daye has announced the launch of a comprehensive gynaecological health consultation and pharmacy service. This new service aims to provide women with faster access to healthcare, offering advice, diagnosis, and prescriptions. Specialist nurses, vetted and NHS-trained with over 20 years of experience, will offer in-depth, personalized advice on period pain, vaginal and sexual health, fertility, and menopause. This service…
